Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 0.75 |
| ▸ | ATM | Q13315 | 7/20 | 0.67 |
| ▸ | ATR | Q13535 | 7/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748358 | 0.90 | MTOR (0.75) | MTORATMATRPIK3CA | |
| SCHEMBL16748269 | 0.90 | MTOR (0.75) | MTORATMATRPIK3CA | |
| SCHEMBL16748142 | 0.90 | MTOR (0.75) | MTORATMATRPIK3CA | |
| Hydrochloric Acid SCHEMBL18091384 | 0.89 | MTOR (0.73) | MTORATMATRPIK3CA | |
| Hydrochloric Acid SCHEMBL18091304 | 0.89 | MTOR (0.73) | MTORATMATRPIK3CA | |
| Hydrochloric Acid SCHEMBL18091307 | 0.89 | MTOR (0.73) | MTORATMATRPIK3CA | |
| SCHEMBL16748242 | 0.88 | MTOR (0.65) | MTORATMATRPIK3CAKCNH2 | |
| SCHEMBL18091380 | 0.88 | MTOR (0.65) | MTORATMATRPIK3CAKCNH2 | |
| SCHEMBL18091260 | 0.88 | MTOR (0.68) | MTORPIK3CA | |
| SCHEMBL16748367 | 0.88 | MTOR (0.68) | MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072893-B1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO LTD (CN) | 2020-03-18 | — | — | EP | disclosed |
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO. LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| EP-3072893-A1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Beijing Forelandpharma Co. Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015074516-A1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | 北京富龙康泰生物技术有限公司 | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DMPK, MAP3K15, MAP4K2 | MTOR 69/4885ATM 273/4885ATR 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.